Welcome to NASHnet.ca's Conference Page

6 reasons to come

1. Learn how to integrate NAFLD Screening into secondary and tertiary care
2. Discover the regulatory pathways for approval of biomarkers in NAFLD patients
3. Review the current and potential biomarkers for staging
4. Investigate if targeting fructose metabolism offers a NAFLD/NASH therapy
5. Hear how belapectin, a galectin-3 (Gal-3) inhibitor, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis
6. Explore the Epidemiology of NAFLD

A discount code for a 15% discount is FATLI15